title: Which domains should be included in a core set for endpoints in ankylosing spondylitis? Introduction to the ankylosing spondylitis module of OMERACT IV.
authors.affiliation: Division of Rheumatology, University Hospital, Maastricht, The Netherlands.
authors.forename: D
authors.initials: D
authors.lastname: van der Heijde
authors.forename: S
authors.initials: S
authors.lastname: van der Linden
authors.forename: N
authors.initials: N
authors.lastname: Bellamy
authors.forename: A
authors.initials: A
authors.lastname: Calin
authors.forename: M
authors.initials: M
authors.lastname: Dougados
authors.forename: M A
authors.initials: MA
authors.lastname: Khan
mesh_terms: D018501:Antirheumatic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000379:methods; D016208:Databases, Factual; D004185:Disability Evaluation; D004493:Education; D006801:Humans; D017063:Outcome Assessment, Health Care / Q000379:methods*; D026741:Physical Therapy Modalities; D011788:Quality of Life; D012720:Severity of Illness Index; D013167:Spondylitis, Ankylosing / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy
chemical_list: D018501:Antirheumatic Agents